司来吉兰联合普拉克索治疗帕金森病合并睡眠障碍的效果观察

Effect of selegiline combined with pramipexole on patients with Parkinson disease with sleep disorder

目的探讨司来吉兰联合普拉克索治疗帕金森病(PD)合并睡眠障碍的疗效。方法抽取聊城市第三人民医院2018年12月至2019年7月收治的PD合并睡眠障碍患者96例,按随机数字表法分为研究组和对照组,每组48例。研究组予以司来吉兰合并普拉克索治疗,对照组予以单纯司来吉兰治疗,记录两组治疗前后精神行为症状、认知障碍、日常生活能力、睡眠质量的改善效果,统计两组治疗期间不良反应发生情况。结果治疗前,两组神经精神科问卷(NPI)、蒙特利尔认知评估量表(MoCA)评分比较差异未见统计学意义(P>0.05);治疗后,两组NPI评分较治疗前下降,MoCA量表评分较治疗前提高(P<0.05),且研究组NPI、MoCA评分均优于对照组(P均<0.05)。治疗前,两组日常生活活动能力量表(ADL)、匹兹堡睡眠质量指数量表(PSQI)评分比较差异未见统计学意义(P>0.05);治疗后,研究组ADL评分高于对照组,PSQI评分低于对照组(P<0.05)。治疗期间,两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论司来吉兰、普拉克索联合治疗PD并睡眠障碍患者有利于改善其精神行为症状、认知障碍、日常生活能力。

Objective To investigate the effect of selegiline combined with pramipexole in the treatment of Parkinson disease(PD)with sleep disorders.Methods A total of 96 PD patients with sleep disorders admitted to the Third People’s Hospital of Liaocheng from December 2018 to July 2019 were selected.They were divided into study group and control group by random number table method,with 48 cases in each group.The study group was treated with selegiline combined with pramipexole,while the control group was treated with selegiline only.The improvement effects of mental and behavioral symptoms,cognitive impairment,activities of daily living and sleep quality of the two groups before and after treatment were recorded,and the occurrence of drug-related adverse reactions in each group during the treatment period was counted.Results There was no significant difference in neuropsychiatric inventory(NPI)and Montreal Cognitive Assessment(MoCA)scores between the two groups before treatment(P>0.05).After treatment,the NPI score of the two groups decreased,and the MoCA score increased,compared with these indexes before treatment(P<0.05);and the NPI and MoCA scores of the study group were better than those of the control group(P<0.05).Before treatment,there was no significant difference in the activities of daily living(ADL)or Pittsburgh sleep quality index(PSQI)scores between the two groups before treatment(P>0.05).After treatment,the ADL score of the study group was higher than that of the control group,and the PSQI score was lower than that of the control group(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions The combination of selegiline and pramipexole in the treatment of PD patients with sleep disorders is conducive to improving their mental and behavioral symptoms,cognitive impairment,and ADL.